Apyx Medical (APYX) AI Stock Analysis

• Market Cap: $149.14M
• Dividend Yield: N/A
• Average Volume (3M): 146.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.27
• Revenue Growth: -1.32%
• EPS Growth: 55.62%
• Country: US
• Employees: 220
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.05
• Shares Outstanding: 38,241,905
• 10 Day Avg. Volume: 162,671
• 30 Day Avg. Volume: 146,668
• PEG Ratio: -0.11
• Price to Book (P/B): 3.95
• Price to Sales (P/S): 1.17
• P/FCF Ratio: -2.99
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 2.12
• Enterprise Value/Gross Profit: 3.38
• Enterprise Value/Ebitda: -12.88
• 1Y Price Target: $6.00
• Price Target Upside: 91.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.33
• Revenue Forecast (FY): $50.81M

• Rating: 60 Neutral
• Price Target: $4.50 ▲(43.77% Upside)

Apyx Medical's stock score is driven by a positive earnings call and strong technical momentum, despite financial challenges and valuation concerns. The successful launch of the AYON Body Contouring System and improved financial health are significant positives, while overbought technical indicators and ongoing losses present risks.

Positive Factors

Product Innovation

The AYON Body Contouring System's strong market acceptance and sales growth demonstrate Apyx Medical's capability to innovate and capture market share in the surgical aesthetics segment.

Revenue Growth

A 12% revenue increase reflects effective market strategies and product demand, indicating potential for sustained growth in the surgical aesthetics market.

Margin Improvement

Improved gross margins suggest better cost management and pricing strategies, enhancing profitability potential and financial health over time.

Negative Factors

Financial Instability

Ongoing financial challenges, including consistent losses, highlight the need for strategic adjustments to ensure long-term stability and growth.

High Debt Levels

High leverage remains a concern, potentially limiting financial flexibility and increasing risk, which could impact the company's ability to invest in growth.

Cash Flow Challenges

Negative cash flows indicate operational inefficiencies and potential liquidity issues, which may hinder the company's ability to fund operations and growth initiatives.

Apyx Medical Business Overview & Revenue Model

Company Description

Apyx Medical Corporation is a medical technology company focused on developing and commercializing innovative products for the surgical and aesthetic markets. The company specializes in advanced energy-based devices, particularly those utilizing its proprietary Renuvion technology, which combines helium plasma and radiofrequency energy for precision in soft tissue and skin procedures. Apyx Medical serves a diverse range of healthcare providers, including plastic surgeons, dermatologists, and other medical professionals, aiming to enhance patient outcomes and improve the overall efficiency of surgical procedures.

How the Company Makes Money

Apyx Medical generates revenue primarily through the sale of its Renuvion devices and consumables, which are used in various surgical and aesthetic applications. The company has established a recurring revenue model through the sale of disposable components that accompany its devices, contributing significantly to its earnings. Additionally, Apyx Medical engages in strategic partnerships with healthcare providers and distributors to expand its market reach and drive adoption of its technologies. These partnerships often include training and support services that promote the effective use of its products, further enhancing revenue opportunities. The company's focus on innovation and expanding its product portfolio also plays a critical role in attracting new customers and retaining existing ones, thereby strengthening its financial performance.

Apyx Medical Financial Statement Overview

Summary

Apyx Medical faces significant financial challenges, with consistent losses impacting profitability and cash flow. While there are improvements in gross profit margin and debt management, the company struggles with operational efficiency and cash flow generation. The financial position reflects a need for strategic adjustments to enhance stability and growth.

Income Statement

Apyx Medical's income statement shows a mixed performance. The company has a gross profit margin of 62.65% TTM, indicating strong cost management. However, the net profit margin is negative at -30.35% TTM, reflecting ongoing losses. Revenue growth is modest at 2.99% TTM, but the EBIT and EBITDA margins are negative, indicating operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 0.79 TTM, which is an improvement from previous years but still indicates leverage concerns. The return on equity is negative, reflecting profitability issues. The equity ratio is not calculated due to missing data, but the overall leverage and equity position suggest financial instability.

Cash Flow

Cash flow analysis shows negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth at -5.36% TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is positive at 1.13, suggesting some efficiency in converting net income to free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.90M	48.10M	52.35M	44.51M	48.52M	27.71M
Gross Profit	30.01M	29.36M	33.76M	29.13M	33.60M	17.50M
EBITDA	-7.88M	-16.80M	-18.11M	-22.01M	-13.91M	-18.48M
Net Income	-14.54M	-23.46M	-18.71M	-23.18M	-15.17M	-11.90M
Balance Sheet
Total Assets	57.37M	64.84M	79.24M	51.77M	68.72M	74.11M
Cash, Cash Equivalents and Short-Term Investments	25.14M	31.74M	43.65M	10.19M	30.87M	41.91M
Total Debt	39.21M	38.76M	38.50M	796.00K	305.00K	676.00K
Total Liabilities	51.28M	50.51M	52.32M	13.98M	14.71M	10.25M
Stockholders Equity	5.85M	14.21M	26.70M	37.58M	53.70M	63.72M
Cash Flow
Free Cash Flow	-9.49M	-18.77M	-5.78M	-21.29M	-11.17M	-16.65M
Operating Cash Flow	-8.41M	-18.05M	-5.25M	-20.28M	-10.45M	-16.07M
Investing Cash Flow	-1.08M	-722.00K	6.73M	-1.01M	-723.00K	-581.00K
Financing Cash Flow	6.86M	6.75M	32.17M	217.00K	24.00K	-73.00K

Apyx Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APYX, the sentiment is Positive. The current price of 3.13 is below the 20-day moving average (MA) of 3.39, above the 50-day MA of 2.80, and above the 200-day MA of 1.90, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 62.93 is Neutral, neither overbought nor oversold. The STOCH value of 77.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APYX.

Apyx Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XTNT	65 Neutral	$103.88M	-20.78	3.64%	―	16.88%	―
APYX	60 Neutral	$149.14M	―	-172.18%	―	-1.32%	55.62%
FONR	59 Neutral	$92.82M	13.30	4.34%	―	3.36%	-21.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIK	49 Neutral	$144.07M	―	-8.73%	―	-31.29%	65.68%
NSPR	48 Neutral	$88.66M	-2.52	-87.61%	―	14.04%	-0.65%
RCEL	42 Neutral	$114.35M	―	-1746.27%	―	20.59%	18.61%

Apyx Medical Corporate Events

Apyx Medical Reports Strong Q3 2025 Results

Apyx Medical Corporation is a surgical aesthetics company known for its innovative products like Renuvion and the AYON Body Contouring System, which are used in cosmetic and hospital surgical markets to provide controlled heat to tissue for desired results.

Apyx Medical’s Earnings Call Highlights AYON Success

Apyx Medical’s recent earnings call highlighted a positive sentiment, driven by the successful launch of the AYON Body Contouring System. The company reported substantial revenue growth in the Surgical Aesthetics segment, which has bolstered their financial outlook despite challenges in OEM and international sales. The strategic focus on AYON and improved financial health contribute to a promising future for the company.

Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study

Study Overview: The clinical study titled ‘Histological Evaluation of Human Skin Biopsies to Assess the Effects of Renuvion APR Treatment as an Adjunct Procedure in Facelift Surgery’ aims to evaluate the impact of the Renuvion device on skin quality. Conducted by Apyx Medical, the study focuses on measuring skin elasticity, hydration, and biological age through DNA methylation in participants undergoing lower facelift surgery.

Apyx Medical Holds Annual Stockholders Meeting

On August 7, 2025, Apyx Medical Corporation held its annual stockholders meeting where several key proposals were voted on. The stockholders elected five directors, ratified RSM US LLP as the independent accounting firm for 2025, approved executive compensation resolutions, and amended the company’s Certificate of Incorporation. These decisions are expected to influence the company’s governance and operational strategies moving forward.

The most recent analyst rating on (APYX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.